HK1209335A1 - Baclofen and acamprosate based therapy of macular degeneration disorders - Google Patents

Baclofen and acamprosate based therapy of macular degeneration disorders

Info

Publication number
HK1209335A1
HK1209335A1 HK15110077.8A HK15110077A HK1209335A1 HK 1209335 A1 HK1209335 A1 HK 1209335A1 HK 15110077 A HK15110077 A HK 15110077A HK 1209335 A1 HK1209335 A1 HK 1209335A1
Authority
HK
Hong Kong
Prior art keywords
baclofen
macular degeneration
based therapy
degeneration disorders
acamprosate
Prior art date
Application number
HK15110077.8A
Other languages
English (en)
Chinese (zh)
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirochkin
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of HK1209335A1 publication Critical patent/HK1209335A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK15110077.8A 2012-07-18 2015-10-14 Baclofen and acamprosate based therapy of macular degeneration disorders HK1209335A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672893P 2012-07-18 2012-07-18
PCT/EP2013/065209 WO2014013025A1 (en) 2012-07-18 2013-07-18 Baclofen and acamprosate based therapy of macular degeneration disorders

Publications (1)

Publication Number Publication Date
HK1209335A1 true HK1209335A1 (en) 2016-04-01

Family

ID=48794112

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110077.8A HK1209335A1 (en) 2012-07-18 2015-10-14 Baclofen and acamprosate based therapy of macular degeneration disorders

Country Status (18)

Country Link
US (1) US9545389B2 (ru)
EP (1) EP2874617B1 (ru)
JP (1) JP6271539B2 (ru)
KR (1) KR20150058159A (ru)
CN (1) CN104780917B (ru)
AU (1) AU2013291970B2 (ru)
BR (1) BR112015001090A2 (ru)
CA (1) CA2879114A1 (ru)
EA (1) EA029157B1 (ru)
ES (1) ES2729208T3 (ru)
HK (1) HK1209335A1 (ru)
IL (1) IL236737B (ru)
IN (1) IN2015DN00820A (ru)
MX (1) MX364232B (ru)
NZ (1) NZ704280A (ru)
SG (1) SG11201500309VA (ru)
WO (1) WO2014013025A1 (ru)
ZA (1) ZA201500663B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2015063140A1 (en) 2013-10-30 2015-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2015121218A1 (en) 2014-02-11 2015-08-20 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485082A4 (en) 2002-02-19 2009-12-30 Xenoport Inc PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
BRPI0413756A (pt) 2003-08-20 2006-10-31 Xenoport Inc composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica
US20050112210A1 (en) * 2003-09-12 2005-05-26 Terry Grossman Eye nutritional supplement
CN102702065A (zh) 2003-12-30 2012-10-03 什诺波特有限公司 酰氧基烃基氨基甲酸酯前药及其中间体的合成
EP2117517B1 (en) 2007-01-11 2011-06-01 XenoPort, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US9308260B2 (en) 2007-07-05 2016-04-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anticonvulsive pharmaceutical compositions
US20090069419A1 (en) 2007-09-07 2009-03-12 Bernd Jandeleit Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090082464A1 (en) 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200932734A (en) 2007-10-15 2009-08-01 Xenoport Inc Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200936123A (en) 2007-11-06 2009-09-01 Xenoport Inc Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
WO2009096985A1 (en) 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
US20100137442A2 (en) 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
WO2010089355A1 (en) * 2009-02-04 2010-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
WO2010102071A1 (en) * 2009-03-03 2010-09-10 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
WO2010120370A2 (en) 2009-04-17 2010-10-21 Xenoport, Inc. Gamma-amino-butyric acid derivatives as gabab receptor ligands
CN103596562B (zh) * 2011-03-01 2016-06-01 法耐斯特公司 基于巴氯芬和阿坎酸的神经性障碍疗法

Also Published As

Publication number Publication date
IN2015DN00820A (ru) 2015-06-12
JP2015522601A (ja) 2015-08-06
CA2879114A1 (en) 2014-01-23
CN104780917B (zh) 2017-09-08
AU2013291970B2 (en) 2017-09-28
ES2729208T3 (es) 2019-10-30
KR20150058159A (ko) 2015-05-28
SG11201500309VA (en) 2015-02-27
EA201500143A1 (ru) 2015-05-29
IL236737B (en) 2018-12-31
CN104780917A (zh) 2015-07-15
JP6271539B2 (ja) 2018-01-31
IL236737A0 (en) 2015-02-26
BR112015001090A2 (pt) 2017-06-27
ZA201500663B (en) 2016-10-26
US9545389B2 (en) 2017-01-17
US20150238452A1 (en) 2015-08-27
WO2014013025A1 (en) 2014-01-23
AU2013291970A1 (en) 2015-02-19
MX2015000777A (es) 2015-10-14
EA029157B1 (ru) 2018-02-28
NZ704280A (en) 2017-06-30
EP2874617A1 (en) 2015-05-27
MX364232B (es) 2019-04-16
EP2874617B1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
HK1203158A1 (en) Baclofen and acamprosate based therapy of neurological disorders
HK1210968A1 (en) Compositions and treatment for eye diseases and disorders
HK1214832A1 (zh) 用於代謝病症和疾病治療的組合物和方法
SG2014008080A (en) Methods of treatment of retinal degeneration diseases
HK1213794A1 (zh) 聯合治療及用於治療脫髓鞘病症的用途
HK1198909A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
HK1208371A1 (en) Methods and compositions for treatment of retinal degeneration
HK1209335A1 (en) Baclofen and acamprosate based therapy of macular degeneration disorders
IL256992B (en) Baclofen and acamprosate based therapy of neurogical disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230716